Total Payments
$1.8M
2024 Payments
$386,894
Companies
52
Transactions
2,414
Medicare Patients
14,504
Medicare Billing
$1.2M
Payment Breakdown by Category
Other$1.4M (79.8%)
Travel$187,231 (10.5%)
Consulting$120,254 (6.7%)
Food & Beverage$52,620 (2.9%)
Education$49.06 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.3M | 534 | 73.9% |
| Travel and Lodging | $187,231 | 800 | 10.5% |
| Consulting Fee | $120,254 | 39 | 6.7% |
| Honoraria | $94,370 | 36 | 5.3% |
| Food and Beverage | $52,620 | 1,001 | 2.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $10,692 | 2 | 0.6% |
| Education | $49.06 | 2 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $489,647 | 777 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $308,792 | 371 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $302,167 | 273 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $291,977 | 294 | $0 (2024) |
| Alnylam Pharmaceuticals Inc. | $90,610 | 105 | $0 (2024) |
| Akcea Therapeutics, Inc. | $84,004 | 121 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $80,722 | 95 | $0 (2024) |
| Lexicon Pharmaceuticals, Inc. | $39,212 | 59 | $0 (2024) |
| Boston Scientific Corporation | $36,829 | 62 | $0 (2024) |
| Lilly USA, LLC | $29,038 | 24 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $386,894 | 450 | E.R. Squibb & Sons, L.L.C. ($122,618) |
| 2023 | $277,660 | 322 | E.R. Squibb & Sons, L.L.C. ($146,313) |
| 2022 | $166,246 | 187 | Boehringer Ingelheim Pharmaceuticals, Inc. ($86,678) |
| 2021 | $105,817 | 147 | Boehringer Ingelheim Pharmaceuticals, Inc. ($52,709) |
| 2020 | $133,998 | 157 | Amgen Inc. ($57,262) |
| 2019 | $298,455 | 470 | Amgen Inc. ($117,593) |
| 2018 | $241,721 | 413 | Amgen Inc. ($103,354) |
| 2017 | $173,117 | 268 | Novartis Pharmaceuticals Corporation ($89,580) |
All Payment Transactions
2,414 individual payment records from CMS Open Payments — Page 1 of 97
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | PFIZER INC. | VYNDAQEL (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,150.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $7.55 | General |
| Category: Cardiovascular | ||||||
| 12/16/2024 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $6.05 | General |
| Category: Cardiovascular | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Travel and Lodging | In-kind items and services | $29.55 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 12/05/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,500.00 | General |
| Category: Cardiovascular | ||||||
| 12/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Travel and Lodging | In-kind items and services | $1,079.10 | General |
| Category: DIABETES | ||||||
| 12/04/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: DIABETES | ||||||
| 12/02/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,463.00 | General |
| Category: Genetic Disease | ||||||
| 12/02/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,463.00 | General |
| Category: Genetic Disease | ||||||
| 12/02/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,868.00 | General |
| Category: Genetic Disease | ||||||
| 12/02/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,380.00 | General |
| Category: Genetic Disease | ||||||
| 12/02/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | Cash or cash equivalent | $188.49 | General |
| Category: Genetic Disease | ||||||
| 12/02/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | Cash or cash equivalent | $6.28 | General |
| Category: Genetic Disease | ||||||
| 11/27/2024 | Merck Sharp & Dohme LLC | VERQUVO (Drug), VERQUVO | Food and Beverage | In-kind items and services | $17.48 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/22/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $24.09 | General |
| Category: Cardiovascular | ||||||
| 11/21/2024 | AstraZeneca Pharmaceuticals LP | WAINUA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,300.00 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 11/21/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $21.15 | General |
| Category: Cardiovascular | ||||||
| 11/19/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | In-kind items and services | $361.96 | General |
| Category: Genetic Disease | ||||||
| 11/19/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Travel and Lodging | In-kind items and services | $185.27 | General |
| Category: Genetic Disease | ||||||
| 11/19/2024 | Alnylam Pharmaceuticals Inc. | AMVUTTRA (Drug) | Food and Beverage | In-kind items and services | $115.31 | General |
| Category: Genetic Disease | ||||||
| 11/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $577.43 | General |
| Category: Cardiovascular | ||||||
| 11/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $525.03 | General |
| Category: Cardiovascular | ||||||
| 11/17/2024 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Travel and Lodging | Cash or cash equivalent | $393.30 | General |
| Category: Cardiovascular | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 23 | 3,452 | 16,938 | $1.9M | $357,633 |
| 2022 | 26 | 3,943 | 5,460 | $1.8M | $303,098 |
| 2021 | 29 | 3,918 | 5,395 | $1.7M | $290,052 |
| 2020 | 22 | 3,191 | 4,229 | $1.4M | $226,507 |
Total Patients
14,504
Total Services
32,022
Medicare Billing
$1.2M
Procedure Codes
106
All Medicare Procedures & Services
106 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 25 | 12,212 | $415,208 | $114,545 | 27.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 320 | 533 | $460,512 | $77,883 | 16.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 481 | 627 | $388,113 | $61,204 | 15.8% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 153 | 168 | $167,832 | $29,304 | 17.5% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 874 | 1,476 | $194,832 | $17,052 | 8.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 60 | 60 | $63,300 | $10,446 | 16.5% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 680 | 886 | $33,668 | $6,156 | 18.3% |
| 93880 | Ultrasound of both sides of head and neck blood flow | Office | 2023 | 28 | 28 | $27,608 | $4,664 | 16.9% |
| 93784 | Ambulatory blood pressure monitoring, 1 day or longer, with recording, scanning analysis, interpretation, and report | Office | 2023 | 116 | 116 | $26,680 | $4,429 | 16.6% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 30 | 43 | $23,994 | $4,285 | 17.9% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 107 | 117 | $22,113 | $4,048 | 18.3% |
| 93224 | Electrocardiogram (ecg) 2-day continuous with review and report by health care professional | Office | 2023 | 57 | 61 | $22,692 | $3,710 | 16.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 37 | 53 | $19,663 | $3,596 | 18.3% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 53 | 53 | $17,013 | $3,111 | 18.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $13,838 | $2,528 | 18.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 16 | 19 | $11,704 | $2,141 | 18.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 14 | 14 | $8,526 | $1,559 | 18.3% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 70 | 79 | $8,690 | $1,518 | 17.5% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 145 | 160 | $2,376 | $1,336 | 56.2% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 17 | 17 | $5,916 | $1,289 | 21.8% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 61 | 67 | $4,221 | $746.16 | 17.7% |
| 99211 | Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | Office | 2023 | 13 | 36 | $4,212 | $685.44 | 16.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 28 | 46 | $3,220 | $586.96 | 18.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 17 | 17 | $1,020 | $581.40 | 57.0% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Office | 2023 | 33 | 33 | $1,254 | $229.68 | 18.3% |
About Dr. Richard Wright, M.D
Dr. Richard Wright, M.D is a Cardiovascular Disease healthcare provider based in Santa Monica, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/30/2005. The National Provider Identifier (NPI) number assigned to this provider is 1770580151.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Richard Wright, M.D has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $386,894 received in 2024. These payments were reported across 2,414 transactions from 52 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.3M).
As a Medicare-enrolled provider, Wright has provided services to 14,504 Medicare beneficiaries, totaling 32,022 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 106 distinct procedure/service records.
Ad
Practice Information
- Specialty Cardiovascular Disease
- Other Specialties Advanced Heart Failure and Transplant Cardiology
- Location Santa Monica, CA
- Active Since 06/30/2005
- Last Updated 07/27/2021
- Taxonomy Code 207RC0000X
- Entity Type Individual
- NPI Number 1770580151
Products in Payments
- Repatha (Biological) $471,528
- ENTRESTO (Drug) $262,073
- JARDIANCE (Drug) $248,223
- CAMZYOS (Drug) $237,538
- AMVUTTRA (Drug) $84,734
- TEGSEDI (Drug) $79,004
- WAINUA (Drug) $72,685
- PRADAXA (Drug) $64,080
- Inpefa (Drug) $39,172
- WATCHMAN (Device) $31,772
- ELIQUIS (Drug) $28,601
- LEQVIO (Drug) $24,360
- Corlanor (Drug) $14,388
- PRALUENT (Drug) $8,293
- VYNDAQEL (Drug) $7,468
- ONPATTRO (Drug) $5,877
- THERAPIES (Device) $4,270
- FARXIGA (Drug) $3,978
- Veltassa (Drug) $2,777
- XARELTO (Drug) $876.14
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Cardiovascular Disease Doctors in Santa Monica
Shephal Doshi, M.d, M.D
Cardiovascular Disease — Payments: $2.0M
Cardiovascular Disease $2.0M
Vikram Rajan, M.d, M.D
Cardiovascular Disease — Payments: $37,005
Cardiovascular Disease $37,005
Peter Pelikan, M.d, M.D
Cardiovascular Disease — Payments: $18,000
Cardiovascular Disease $18,000
Dr. George Grifka, M.d, M.D
Cardiovascular Disease — Payments: $12,998
Cardiovascular Disease $12,998
Alexandra Lajoie, M.d, M.D
Cardiovascular Disease — Payments: $9,422
Cardiovascular Disease $9,422
Dr. Christiane Schaeffler, M.d, M.D
Cardiovascular Disease — Payments: $6,604
Cardiovascular Disease $6,604